SCHEMBL3548272

SCHEMBL3548272

O=C(O)COc1ccc(-c2cc(Cl)c(C(C3CCCCC3)C3CCNC3=O)c(Cl)c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.37
FABP1 P07148 2/20 0.37
NR1H4 Q96RI1 2/20 0.37
MEN1 O00255 2/20 0.37
ADRB3 P13945 1/20 0.36
PTGES O14684 2/20 0.36
PTGS2 P35354 1/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.36
BLM P54132 1/20 0.36
GPR35 Q9HC97 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
PPARD Q03181 2/20 0.35
PPARG P37231 1/20 0.35
PTGDR2 Q9Y5Y4 4/20 0.35
PTGDR Q13258 3/20 0.35
PTGER2 P43116 1/20 0.35
MAP4K4 O95819 1/20 0.35
MCL1 Q07820 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999221 0.91 MMP2 (0.41) PTGS2FFAR4PTGDR2
SCHEMBL3554796 0.91 FFAR4 (0.41) KMT2AMEN1FFAR4PTGDR2
SCHEMBL3001081 0.89 ESR1 (0.43) KMT2AMEN1NPC1POLBRAB9A
SCHEMBL2998775 0.84 MEN1 (0.38) KMT2AMEN1
SCHEMBL209307 0.84 PDE4D (0.41) NR1H4ADRB3PTGES
SCHEMBL2989144 0.83 PSEN1 (0.43) NR1H4PTGESPTGS2FFAR4
SCHEMBL3004306 0.83 PPARA (0.39) KMT2AFABP1NR1H4MEN1POLB
SCHEMBL209957 0.83 USP5 (0.40)
SCHEMBL3548869 0.81 FFAR4 (0.42) KMT2AMEN1FFAR4PTGDR2
SCHEMBL208481 0.80 SLC6A3 (0.41) KMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713979-B2 Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2010-05-11 US claimed
EP-1807072-B1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2009-01-07 EP claimed
US-20080275043-A1 Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 ELI LILLY AND COMPANY 2008-11-06 US claimed
EP-1807072-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-07-18 EP claimed
WO-2006049952-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2006-05-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275043-A1 Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 HSD11B1, HSDL2, HSD17B1 KMT2A 2240/4885FABP1 181/4885NR1H4 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.